Chemed Corporation
NYSE:CHEMedical - Care Facilities
+$4.91 today
- Market cap
- $7.12B
- Beta
- 0.54
- P/E (TTM)
- 23.2
- EPS (TTM)
- $19.00
- Dividend yield
- 0.54%
Volume 0.17M
Average 0.25M
CHE Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Chemed CorporationNYSE: CHE
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development remains negative
Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How CHE compares with its peers on the latest reported figures
- CHE's LTM Jun 2026 research & development of $0 is the highest of the 5 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for CHE, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Oct 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CHE) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for CHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.14B | 2.13B | 2.26B | 2.43B | 2.53B |
| Cost of Revenue | 1.37B | 1.37B | 1.47B | 1.58B | 1.77B |
| Gross Profit | 769.8M | 765.09M | 798.82M | 854.35M | 758.34M |
| Gross Margin | 36.0% | 35.8% | 35.3% | 35.1% | 30.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 366.73M | 358.73M | 395.12M | 424.36M | 417.19M |
| Operating Expenses | 426.77M | 421.59M | 458.25M | 487.86M | 417.19M |
| Depreciation & Amortization | 59.05M | 59.17M | 60.87M | 63.05M | 64.84M |
| EBITDA | 411.23M | 393.44M | 414.34M | 464.29M | 422.37M |
| EBITDA Margin | 19.2% | 18.4% | 18.3% | 19.1% | 16.7% |
| Operating Income | 343.04M | 343.5M | 340.57M | 366.49M | 338.25M |
| Operating Margin | 16.0% | 16.1% | 15.0% | 15.1% | 13.4% |
| Interest Income | 377K | 355K | 6.27M | 14.61M | 8.75M |
| Interest Expense | 1.87M | 4.58M | 3.11M | 1.78M | 1.75M |
| Other Income / Expenses | 7.28M | (13.82M) | 9.8M | 32.97M | 17.53M |
| Income Before Tax | 350.31M | 329.68M | 350.37M | 399.47M | 355.78M |
| Pre-Tax Margin | 16.4% | 15.4% | 15.5% | 16.4% | 14.1% |
| Income Tax Expense | 81.76M | 80.06M | 77.86M | 97.47M | 90.54M |
| Net Income | 268.55M | 249.62M | 272.51M | 302M | 265.24M |
| Net Margin | 12.6% | 11.7% | 12.0% | 12.4% | 10.5% |
| EPS (Basic) | 17.14 | 16.72 | 18.11 | 20.10 | 18.42 |
| EPS (Diluted) | 16.85 | 16.53 | 17.93 | 19.89 | 18.42 |
| Weighted Avg Shares | 15.67M | 14.93M | 15.05M | 15.02M | 14.4M |
| Weighted Avg Shares (Diluted) | 15.94M | 15.1M | 15.2M | 15.19M | 14.4M |
Chemed Corporation
NYSE:CHE
Intrinsic Alpha fair value
Locked
Current Price
$546.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.